Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

FDA issues complete response letter regarding Byuderon NDA

Oct. 21, 2010

New diacylglycerol O-acyltransferase 1 inhibitors disclosed

Oct. 21, 2010

Treatment begins in phase I/II alpha-1-antitrypsin trial in type 1 diabetes

Oct. 21, 2010

Zealand Pharma's ZP-2307 shows bone anabolic activity in vivo

Oct. 21, 2010

Merck & Co. claims new diacylglycerol O-acyltransferase 1 inhibitors

Oct. 20, 2010

FDA grants fast track status for HPN-100 in urea cycle disorders

Oct. 20, 2010

DiaMedica reports final data from DM-99 study in type 1 diabetes

Oct. 20, 2010

Pfizer presents new GPR119 receptor agonists

Oct. 18, 2010

Merck & Co. claims new diacylglycerol O-acyltransferase 1 inhibitors

Oct. 15, 2010

FDA warns of increased risk of thigh bone fracture with bisphosphonates use

Oct. 15, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...